Loading...
Found 61 results for site-public-contact
A listing of site-public-contact medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A phase 2, randomised, multi-centre, open label trial to evaluate the safety and efficacy ofintravesical nadofaragene firadenovec alone or in combination with chemotherapy(gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with high-grade Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) (ABLE-22)
H
Hristos Kaimakliotis, MD
The pivotal phase 2 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and efficacy of intravesical instillation of nadofaragene firadenovec alone or in combination …
Phase I/II Trial of Lurbinectedin with Osimertinib in Transformed Small Cell Lung Cancer
M
Misty D. Shields, MD, PhD
Primary Objective:To assess the efficacy of the combination of lurbinectedin with osimertinib in patients with EGFR altered non-small cell lung cancer (NSCLC) with documented transformation to SCLC, after the use of EGFR tyrosine kinase inhibitor osimertinib.Secondary ObjectiveTo evaluate the safety of the combination of lurbinectedin with osimertinib in patients with …
PSMAcTION: A phase II/III, open-label, international, multi-center, randomized study of AAA817 versus standard of care in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA targeted therapy.
N
Nabil Adra, MD
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy.Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is …
Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer
T
Tarah Ballinger, MD
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not …
A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
R
Rohan Maniar
What is the purpose of this study?This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC …
FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer with FGFR3 Alterations
T
Tareq Salous
This is an open-label, multi-center, phase 1a/b study in participants with FGFR3-altered advanced solid tumors, including metastatic urothelial cancer (UC). The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that …
A Prospective Low-Interventional Phase 4 Single Arm Study of Ocular Assessments in Patients Treated with Tivdak® in Recurrent or Metastatic Cervical Cancer
S
Sharon E. Robertson
TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to …
PATIENTS PERSPECTIVES ON TREATMENT DECISION-MAKING AND THE ACCEPTABILITY AND USABILITY OF THE INTERACTIVE WEB-ENABLED COMMUNICATION RESOURCES OF THE CLL/SLL CARE ROAD MAP
L
Larry Cripe, MD
The purpose of the study is to understand how people think about choosing between two or more treatment options and then to seek their reactions to the CLL Mind Map and Patient First Resources. Interested in participating? For more information about this research study or other cancer-related clinical trials at Indiana …
A Randomized Phase Ii/Iii Study of Docetaxel and Ramucirumab with or Without Cemiplimab (Regn2810) for Participants Previously Treated with Platinum-Based Chemotherapy and Immunotherapy for Stage Iv or Recurrent Non-Small Cell Lung Cancer (Lung-Map Non-Matched Sub-Study)
R
Rohan Maniar
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody …
Evaluating Financial Barriers to Breast Cancer Patients Participating in Clinical Trials
K
Kathy Miller, MD
The purpose of this study is to understand the indirect costs (i.e., lost income, travel costs, parking costs, etc.) taken on by breast cancer patients who have enrolled in cancer clinical trials.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive …
Please choose between Voice or SMS based delivery of verification code
or